Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.35 |
| ▸ | GART | P22102 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885924 | 1.00 | TYMS (0.37) | TYMSDHFRKDRP2RY12GART | |
| SCHEMBL9724178 | 0.87 | TYMS (0.38) | TYMSDHFRKDRP2RY12GART | |
| SCHEMBL9724176 | 0.87 | TYMS (0.38) | TYMSDHFRKDRP2RY12GART | |
| SCHEMBL9782470 | 0.86 | ALOX5 (0.36) | TYMSDHFRKDRP2RY12TDP1 | |
| SCHEMBL8721880 | 0.86 | ALOX5 (0.36) | TYMSDHFRKDRP2RY12TDP1 | |
| SCHEMBL9228554 | 0.86 | ALOX5 (0.36) | TYMSDHFRKDRP2RY12TDP1 | |
| SCHEMBL6885650 | 0.85 | POLB (0.41) | TYMSDHFRGARTTDP1CYP3A4 | |
| SCHEMBL6885646 | 0.85 | POLB (0.41) | TYMSDHFRGARTTDP1CYP3A4 | |
| SCHEMBL9555886 | 0.83 | L3MBTL1 (0.52) | TYMSDHFRGARTKDM4E | |
| SCHEMBL9555878 | 0.83 | L3MBTL1 (0.52) | TYMSDHFRGARTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259878-A1 | Fluoromethotrexates and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259878-A1 | Fluoromethotrexates and uses therefor | MTX1, DHFR, SLC46A1 | TYMS 22/4885DHFR 2/4885KDR 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.